Last updated: 24 July 2019 at 7:21pm EST

Beatrice J Cazala Net Worth

The estimated Net Worth of Beatrice J Cazala is at least $13.7 Milion dollars as of 31 May 2013. Beatrice Cazala owns over 91,282 units of Bristol-Myers Squibb Co stock worth over $8,424,243 and over the last 16 years Beatrice sold BMY stock worth over $5,324,254.

Beatrice Cazala BMY stock SEC Form 4 insiders trading

Beatrice has made over 22 trades of the Bristol-Myers Squibb Co stock since 2009, according to the Form 4 filled with the SEC. Most recently Beatrice sold 91,282 units of BMY stock worth $4,290,254 on 31 May 2013.

The largest trade Beatrice's ever made was exercising 179,678 units of Bristol-Myers Squibb Co stock on 7 March 2013 worth over $2,474,166. On average, Beatrice trades about 32,240 units every 67 days since 2009. As of 31 May 2013 Beatrice still owns at least 173,374 units of Bristol-Myers Squibb Co stock.

You can see the complete history of Beatrice Cazala stock trades at the bottom of the page.

What's Beatrice Cazala's mailing address?

Beatrice's mailing address filed with the SEC is ROUTE 206 & PROVINCE LINE ROAD, , PRINCETON, NJ, 08543.

Insiders trading at Bristol-Myers Squibb Co

Over the last 16 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius a Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.

What does Bristol-Myers Squibb Co do?

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Complete history of Beatrice Cazala stock trades at Bristol-Myers Squibb Co

Osoba	Trans. Transakce	Celková cena
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Prodej	$4,290,254 31 May 2013
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Prodej	$1,034,000 30 May 2013
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$2,782,247 23 May 2013
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$2,474,166 7 Mar 2013
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$135,747 6 Mar 2013
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$3,927,516 10 Aug 2012
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$1,862,531 6 Mar 2012
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$527,952 1 Mar 2012
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$70,832 12 Mar 2011
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$201,449 6 Mar 2011
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$172,373 2 Mar 2011
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$861,151 1 Mar 2011
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$82,550 1 Jul 2010
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$59,269 5 Apr 2010
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$69,411 12 Mar 2010
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$192,659 6 Mar 2010
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$411,489 2 Mar 2010
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$63,710 1 Mar 2010
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$67,993 1 Jul 2009
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$44,656 5 Apr 2009
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$55,711 12 Mar 2009
Beatrice J Cazala SVP Comm Ops a Pres GC Euro EM	Využití opce	$73,895 6 Mar 2009

Bristol-Myers Squibb Co executives and stock owners

Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include:

Giovanni Caforio,
Chairman of the Board, Chief Executive Officer
Sandra Leung,
Executive Vice President, General Counsel
Dr. Giovanni Caforio M.D.,
Chairman & CEO
Christopher Boerner,
Executive Vice President and Chief Commercial Officer
David Elkins,
Executive Vice President and Chief Financial Officer Member of the Leadership Team
Rupert Vessey,
Executive Vice President, Research and Early Development Member of the Leadership Team
Louis Schmukler,
Executive Vice President, President - Global Product Development and Supply
David V. Elkins,
Exec. VP & CFO
Rupert Vessey BCH, BM, DPHIL, M.A.,
Exec. VP and Pres of Research & Early Devel.
Sandra Leung Esq.,
Exec. VP & Gen. Counsel
Dr. Christopher S. Boerner,
Exec. VP & Chief Commercialization Officer
Vicki Sato,
Lead Independent Director
Matthew Emmens,
Independent Director
Peter Arduini,
Independent Director
Dinesh Paliwal,
Independent Director
Theodore Samuels,
Independent Director
Karen Vousden,
Independent Director
Robert Bertolini,
Independent Director
Gerald Storch,
Independent Director
Phyllis Yale,
Independent Director
Julia Haller,
Independent Director
Michael Bonney,
Independent Director
Derica Rice,
Independent Director
Paula Price,
Independent Director
Tim Power,
Vice President of Investor Relations
Joseph Eid,
Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team
Karen Santiago,
Senior Vice President, Corporate Controller
Adam Dubow,
Senior Vice President, Chief Compliance Officer and Ethics Officer
Paul von Autenried,
Chief Information Officer, Senior Vice President
Elizabeth Mily,
Executive Vice President - Strategy & Business Development
Kathryn Metcalfe,
Executive Vice President - Corporate Affairs Member of the Leadership Team
Samit Hirawat,
Executive Vice President, Chief Medical Officer, Global Drug Development Member of the Leadership Team
Nadim Ahmed,
Executive Vice President and President - Hematology
John Elicker,
Executive Vice President of Investor Relations
Ann Judge,
Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
Ann M. Powell Judge,
Exec. VP & Chief HR Officer
Adam Dubow,
Sr. VP, Chief Compliance & Ethics Officer
Timothy Power,
VP & Head of Investor Relations
Paul von Autenried,
Exec. VP & Chief Information Officer
Greg Meyers,
Exec. VP and Chief Digital & Technology Officer
Jose Baselga,
Director
Alan J Lacy,
Director
Joseph C Caldarella,
VP & Financial Controller
Anne Nielsen,
Chief Compliance & Ethics Off
Laurie H M.D. Glimcher,
Director
Michael Grobstein,
Director
Togo D Jr West,
Director
Emmanuel Blin,
SVP, Head of Commercialization
Francis M Cuss,
SVP Dscvry & Exp Clinl Resrch
Murdo Gordon,
SVP, Head of Worldwide Markets
Thomas J. Jr. Lynch,
Director
Karin Shanahan,
EVP, Glob. Prod. Dev. & Supply
Lynelle Hoch,
President, Cell Therapy Org.
Phil M Holzer,
SVP and Controller
Ahn Amanda Poole,
EVP, Chief Human Resources
Samuel J Moed,
SVP, Strat Plan & Analysis
Michelle Weese,
EVP, Corporate Affairs
Paul Biondi,
SVP, Head of Strategy & BD
Charles A Bancroft,
EVP, Head of Integration
Ann Powell,
EVP, Chief Human Resources
Frances K Heller,
SVP, Business Development
Brian Daniels,
SVP Global Development
Elliot Sigal,
EVP, CSO & President R&D
Beatrice J Cazala,
SVP Comm Ops & Pres GC Euro EM
Robert T Zito,
SVP & Chief Comm Officer
Jeremy M Levin,
SVP Strat Transactions
R Sanders Williams,
Director
Anthony C Hooper,
President US Pharmaceuticals
Louis J Freeh,
Director
Anthony A Mcbride,
SVP Human Resources
De Notaristefani Carlo,
President, Tech Ops
Leif Johansson,
Director
John E Celentano,
SVP Strat & Productivity Trans
Jean Marc Huet,
SVP & CFO
James M Cornelius,
Chairman & CEO
Lewis B Campbell,
Director
Medina Manuel Hidalgo,
Director
Benjamin Hickey,
President, RayzeBio Org.
Gregory Scott Meyers,
EVP, Chief Digital & Tech Off.
Sharon Greenlees,
SVP & Controller
Deepak Bhatt,
Director
Michael R. Mc Mullen,
Director
Adam Lenkowsky,
EVP, Chief Commercial Officer
Robert M Plenge,
EVP, Chief Research Officer
Cari Gallman,
EVP, Corporate Affairs